Search Results - "Thomas, RV"

Judging Nudging: Answering the Manipulation Objection by Nys, Thomas RV, Engelen, Bart

“…Is it ever justified to ‘nudge’ people towards their own health? In this article, we argue that it is. We do so by arguing (1) that nudges are not necessarily…”
Get full text

Interferon γ (IFN-γ) polymorphism in posttransplantation lymphoproliferative disease by Thomas, Ranjit V., McAulay, Karen, Higgins, Craig, Wilkie, Gwen, Crawford, Dorothy H.

Get full text

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT) by Yarchoan, R, Perno, C F, Thomas, R V, Klecker, R W, Allain, J P, Wills, R J, McAtee, N, Fischl, M A, Dubinsky, R, McNeely, M C

“…Five dose regimens of 2',3'-dideoxycytidine (ddC) were administered, intravenously for 2 weeks then orally for 4 or more weeks, to 20 patients with acquired…”
Get more information

In vivo Activity against HIV and Favorable Toxicity Profile of 2$^{\prime}$,3$^{\prime}$-Dideoxyinosine by Yarchoan, Robert, Mitsuya, Hiroaki, Thomas, Rose V., Pluda, James M., Hartman, Neil R., Perno, Carlo-Federico, Marczyk, Kathy S., Allain, Jean-Pierre, Johns, David G., Broder, Samuel

“…The purine analog 2$^{\prime}$,3$^{\prime}$-dideoxyinosine (ddI), which has anti-retroviral activity in vitro was administered for up to 42 weeks to 26…”
Get full text

The successful use of plasma exchange and immunosuppression in the management of acquired glanzmann's thrombasthenia by Thomas, R. V., Bessos, H., Turner, M. L., Horn, E. H., Ludlam, C. A.

Get full text

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex by Yarchoan, R, Pluda, J M, Thomas, R V, Mitsuya, H, Brouwers, P, Wyvill, K M, Hartman, N, Johns, D G, Broder, S

“…To evaluate the long-term toxicity and activity profile of 2',3'-dideoxyinosine (ddI), a potent inhibitor of human immunodeficiency virus (HIV) replication, in…”
Get more information

Internal jugular vein thrombosis following in-vitro fertilization in a woman with protein S deficiency and heterozygosity for the prothrombin 3′ UTR mutation, despite anticoagulation with heparin by Thomas, R V, Reid, W, Perry, D J

“…We report the case of a 31-year-old woman with protein S deficiency and heterozygosity for the prothrombin 3′ UTR mutation who developed an internal jugular…”
Get full text

Spatial alignment of molecules by intense, linearly-polarized light fields and the effects of space charge by Safvan, C.P, Thomas, R.V, Mathur, D

“…Angular distributions are measured of S + and S 2+ fragment ions formed by dissociative ionization of CS 2 by intense (10 13 W cm −2), 532 nm laser pulses of…”
Get full text

A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study by Davidson, KL, Devaney, MB, Tighe, JE, Rogers, SY, Dunlop, DJ, Mackie, MJ, Thomas, RV, Johnson, PR, Scotland and Newcastle Lymphoma Group Study

“…Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. BACKGROUND AND OBJECTIVES: The prognosis in patients with primary refractory or relapsed high…”
Get full text

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection by Hartman, N R, Yarchoan, R, Pluda, J M, Thomas, R V, Marczyk, K S, Broder, S, Johns, D G

“…This article describes the pharmacokinetics of 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxyinosine (ddI) as determined during phase I clinical trials in…”
Get more information

Injuries to 15–19-year olds in road traffic crashes: a cross sectional analysis of police crash data by Thomas, Jamie R. V., Jones, Sarah J.

“…Aim To describe the circumstances in which 15–19-year-old vehicle occupants are injured in road traffic crashes, compared with older casualties. Subjects and…”
Get full text

Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex by de Miranda, P, Good, S S, Yarchoan, R, Thomas, R V, Blum, M R, Myers, C E, Broder, S

“…The anti-human immunodeficiency virus drug zidovudine is metabolized extensively in human beings to the 5'-glucuronide (GAZT) and is cleared rapidly, resulting…”
Get more information

Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI) by Aoki, S, Yarchoan, R, Thomas, R V, Pluda, J M, Marczyk, K, Broder, S, Mitsuya, H

“…A rapid and simple method for determining the proviral DNA content in peripheral blood mononuclear cells (PBM) from patients with human immunodeficiency virus…”
Get more information

Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine by Yarchoan, R, Berg, G, Brouwers, P, Fischl, M A, Spitzer, A R, Wichman, A, Grafman, J, Thomas, R V, Safai, B, Brunetti, A

“…Four patients with human-immuno-deficiency-virus-associated neurological disease were treated with 3'-azido-3'-deoxythymidine (AZT). Three (two with chronic…”
Get more information

Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease by Yarchoan, R, Thomas, R V, Grafman, J, Wichman, A, Dalakas, M, McAtee, N, Berg, G, Fischl, M, Perno, C F, Klecker, R W

“…3'-Azido-2',3'-dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus-associated neurological disease: 3 with dementia, 2…”
Get more information

Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study by Surbone, A, Yarchoan, R, McAtee, N, Blum, M R, Maha, M, Allain, J P, Thomas, R V, Mitsuya, H, Lehrman, S N, Leuther, M

“…On the basis of observation that acyclovir potentiates the in-vitro antiviral activity of 3-azido-2',3'-dideoxythymidine (also known as azidothymidine or…”
Get more information

Initial clinical experience with dideoxynucleosides as single agents and in combination therapy by Yarchoan, R, Pluda, J M, Perno, C F, Mitsuya, H, Thomas, R V, Wyvill, K M, Broder, S

“…Several dideoxynucleosides, including 3'-azido-2',3'-dideoxythymidine (zidovudine, azidothymidine, AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyinosine…”
Get more information

Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272) by SURBONE, A, FORD, H. JR, KELLEY, J. A, BEN-BARUCH, N, THOMAS, R. V, FINE, R, COWAN, K. H

“…A Phase I clinical trial of 1-beta-D-arabinofuranosyl-5-azacytosine (ara-AC or fazarabine) given as a 72-h continuous infusion on a 21-day cycle was conducted…”
Get full text

The National Cancer Institute Phase I Study of 2',3'-Dideoxyinosine Administration in Adults with AIDS or AIDS-Related Complex: Analysis of Activity and Toxicity Profiles by Yarchoan, Robert, Mitsuya, Hiroaki, Pluda, James M., Marczyk, Kathy S., Thomas, Rose V., Hartman, Neil R., Pim Brouwers, Perno, Carlo-Federico, Allain, Jean-Pierre, Johns, David G., Broder, Samuel

“…2',3'-Dideoxyinosine (didanosine; ddI) was administered to 37 adults with AIDS or AIDS-related complex in an escalating-dose phase I study. Groups of three or…”
Get full text